✦ LIBER ✦

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome

✍ Scribed by Donnette A. Dabydeen; Jyothi P. Jagannathan; Nikhil Ramaiya; Katherine Krajewski; Fabio A.B. Schutz; Daniel C. Cho; Ivan Pedrosa; Toni K. Choueiri

Book ID: 116431096
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 407 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.03.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7113 Radiographic findings of drug-induc

7113 Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus

✍ Pablo, M.; Hudes, G.; Dutcher, J.; White, C.; Krygowski, M.; Cincotta, M.; Ohata 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Clinical factors associated with outcome

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

✍ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to

PCN51 HEALTH CARE COSTS ASSOCIATED WITH

PCN51 HEALTH CARE COSTS ASSOCIATED WITH ANGIOGENESIS INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT US COMMUNITY ONCOLOGY CLINICS

✍ K Chen; SP Sarda; L Antràs; S Whittemore; A Luka; P Ramamurthy; J Scott; B Fortn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Third-Line Sorafenib After Sequential Th

Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma

✍ Giuseppe Di Lorenzo; Carlo Buonerba; Piera Federico; Pasquale Rescigno; Michele 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 242 KB

The association of clinical outcome to f

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

✍ Mhd Y. Al-Marrawi, Brian I. Rini, Lauren C. Harshman, Georg Bjarnason… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 269 KB

Cessation of vascular endothelial growth

Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma : Feasibility and clinical outcome

✍ Sarmad Sadeghi; Laurence Albiges; Laura S. Wood; Shari L. Black; Timothy D. Gill 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB